Ibuprofen Injection Approved by FDA to Treat Fever, Pain in Infants
The expanded labeling allows for an intravenously delivered formulation of ibuprofen (Caldolor) in infants aged 3 to 6 months.
The FDA has approved expanded labeling for an intravenously delivered formulation of ibuprofen (Caldolor; Cumberland Pharmaceuticals) to treat fever and pain in infants aged 3 months to 6 months, according to a recent press release from Cumberland Pharmaceuticals.1
With the label expansion, ibuprofen is now approved for use in adults and pediatric patients 3 months and older for the management of mild to moderate pain as a monotherapy, and for the management of moderate to severe pain as an adjunct to an opioid. According to Cumberland Pharmaceuticals, ibuprofen is the only non-opioid product FDA-approved to treat pain in infants that is delivered through injection.
The FDA-approved label includes the product’s indications and usage, appropriate patient populations, clinical study results, potential side effects, patient safety details, and instructions for use in the pediatric patient population.
The expanded label approval follows the established safety and efficacy of ibuprofen to treat pain and fever in patients 3 months and up, demonstrated from 1 adequate and controlled open-label study in infants. Additionally, “Safety data from [4] studies in 164 pediatric patients, supportive pediatric data from other approved ibuprofen products, and evidence from adequate and well-controlled studies in adults,” has further established safety and efficacy according to Cumberland Pharmaceuticals.
This article originally appeared on Contemporary Pediatrics.
Reference:
1. Caldolor now FDA approved for treatment of fever & pain in infants. News Release. Cumberland Pharmaceuticals. May 15, 2023. Accessed May 17, 2023. https://investor.cumberlandpharma.com/news-releases/news-release-details/caldolorr-now-fda-approved-treatment-fever-pain-infants
Socioeconomic Disparities Persisted Alongside Improving Vaccination Rates In US Over 11-Year Period
April 16th 2024Findings indicating that socioeconomic disparities widened gaps in vaccination timeliness signal the need for increased efforts to promote timely vaccination among children from families with lower income and those without private insurance.
FDA Expands Tenofovir Alafenamide Indication to Treat HBV in Patients as Young as 6
March 28th 2024Tenofovir alafenamide was originally approved by the FDA in 2016 to treat adults with chronic HBV infection with compensated liver disease and in 2022 to treat pediatric patients aged 12 years and older.
